ClinicalTrials.gg
CompletedNCT03406377Updated Jun 15, 2021Results posted

Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

A Phase 2 interventional study of OPK-88003 and Placebo in Type 2 Diabetes Mellitus, sponsored by OPKO Health, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-06-15.

Sponsored by OPKO Health, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States — 344 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
1,321st of 2,960
113 · median 90
Started
2018
with 125 others
Phase 2
391 of 3,307
24 open now
Registered
2,043rd of 3,307
by date

Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,321st largest by enrollment of the 2,960 interventional ones that give a count, is one of 126 that started in 2018, is one of 391 in phase 2, and was the 2,043rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

344 of the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC) OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.

Read the detailed description

This clinical trial is a phase 2, double-blind dose escalation regimen of once-weekly OPK-88003 in subjects with T2DM. The trial consists of a screening/baseline (up to 2 weeks prior to first dose), treatment period consisting of a dose escalation (8 weeks) and a target dose (22 weeks), and a follow-up period (4 weeks). Subjects will be randomly assigned to volume-matched OPK-88003 or placebo administered QW.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 to 80 years with T2DM treated with diet and exercise alone or on a stable dose of metformin (≥ 1000 mg/day),
  • ≥27 and ≤45 kg/m2
  • ≥7.0% and ≤10.5% at screening

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Previous treatment with incretin mimetic drugs
  • Have used insulin for diabetic control for more than 6 consecutive days within the prior year
  • Have had two or more emergency room visits or hospitalizations due to poor glucose control within the prior 6 months
  • Have a history of acute or chronic pancreatitis or elevation in serum lipase/amylase (>2 x ).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
113 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Water for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate

    Drug: Placebo

  • Experimental
    OPK-88003

    70 mg/vial (extractable volume 1 mL) (20mg for 4 weeks, 40 mg for 4 weeks and 70 mg for 22 weeks)

    Drug: OPK-88003

Interventions

  • DrugOPK-88003

    OPK-88003 subcutaneous injection

  • DrugPlacebo

    Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Change in HbA1c in Subjects With Type 2 DM

    To evaluate the effect of dose escalation of QW SC OPK-88003 vs placebo injections on HbA1c absolute change from baseline to after 30 weeks treatment in subjects with T2DM inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.

    Time frame: From baseline to 30 weeks

Secondary outcomes

  1. Mean Percent (%) Body Weight Change

    Mean percent (%) body weight change from baseline to after 30 weeks treatment

    Time frame: From baseline to 30 weeks

  2. Percent (%) of Subjects With 5% or Greater Body Weight Loss.

    Percent (%) of subjects with 5% or greater body weight loss after 30 weeks treatment

    Time frame: 30 weeks.

  3. Change From Baseline of Fasting Plasma Glucose (FPG).

    Change of FPG from baseline to after 30 weeks treatment

    Time frame: 30 weeks.

07

Results

Posted Jun 15, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboOPK-88003
Started4172
Completed2551
Not completed1621

Outcome measures

PrimaryChange in HbA1c in Subjects With Type 2 DM

To evaluate the effect of dose escalation of QW SC OPK-88003 vs placebo injections on HbA1c absolute change from baseline to after 30 weeks treatment in subjects with T2DM inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.

Time frame:
From baseline to 30 weeks
Reported as:
Least squares mean · mmols/mol
Change in HbA1c in Subjects With Type 2 DM
mmols/molPlaceboOPK-88003
Change in HbA1c in Subjects With Type 2 DM-0.25 ± 0.209-1.47 ± 0.168
SecondaryMean Percent (%) Body Weight Change

Mean percent (%) body weight change from baseline to after 30 weeks treatment

Time frame:
From baseline to 30 weeks
Reported as:
Least squares mean · Percentage of body weight change
Mean Percent (%) Body Weight Change
Percentage of body weight changePlaceboOPK-88003
Mean Percent (%) Body Weight Change-2.10 ± 0.976-5.83 ± 0.737
SecondaryPercent (%) of Subjects With 5% or Greater Body Weight Loss.

Percent (%) of subjects with 5% or greater body weight loss after 30 weeks treatment

Time frame:
30 weeks.
Reported as:
Number · Percentage of participants
Percent (%) of Subjects With 5% or Greater Body Weight Loss.
Percentage of participantsPlaceboOPK-88003
Percent (%) of Subjects With 5% or Greater Body Weight Loss.16.748.8
SecondaryChange From Baseline of Fasting Plasma Glucose (FPG).

Change of FPG from baseline to after 30 weeks treatment

Time frame:
30 weeks.
Reported as:
Least squares mean · mg/dL
Change From Baseline of Fasting Plasma Glucose (FPG).
mg/dLPlaceboOPK-88003
Change From Baseline of Fasting Plasma Glucose (FPG).-13.3 ± 7.04-46.2 ± 5.86

Adverse events

Collected over 36 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/41 (0%)2/41 (4.9%)5/41 (12.2%)
OPK-880030/72 (0%)9/72 (12.5%)35/72 (48.6%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboOPK-88003
Cecal volvulus s/p right hemicolectomyGastrointestinal disorders1/410/72
SepsisInfections and infestations1/410/72
Acute toxic encephalopathyNervous system disorders1/410/72
Branch retinal artery occlusionEye disorders0/411/72
Branch retinal artery occlusion account for peripheral vision loss right eyeEye disorders0/411/72
Acute cholelithiasisHepatobiliary disorders0/411/72
Acute pancreatitisGastrointestinal disorders0/411/72
Coronary artery diseaseCardiac disorders0/411/72
Hypersensitivity reactionImmune system disorders0/411/72
Systemic inflammatory response syndromeGeneral disorders0/411/72
Most frequent other events
Most frequent other events
EventPlaceboOPK-88003
NauseaGastrointestinal disorders2/4128/72
VomitingGastrointestinal disorders1/4119/72
DiarrhoeaGastrointestinal disorders3/419/72
Lipase increasedInvestigations0/412/72
Acute myocardial infarctionCardiac disorders0/411/72
Abdominal pain upperGastrointestinal disorders0/411/72
Pancreatitis acuteGastrointestinal disorders0/411/72
RetchingGastrointestinal disorders0/411/72
Drug hypersensitivityImmune system disorders0/411/72
HypersensitivityImmune system disorders0/411/72

Baseline characteristics

Age, Continuous
Age, Continuous(Year)PlaceboOPK-88003Total
Mean57.4 ± 9.0653.8 ± 9.9455.1 ± 9.75
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOPK-88003Total
Female242953
Male174360
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOPK-88003Total
Hispanic or Latino233659
Not Hispanic or Latino183654
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOPK-88003Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American61218
White336093
More than one race000
Unknown or Not Reported101
08

Study locations

3 sites
  • National Research Institute - Huntington Park
    Huntington Park, California 90255, United States
  • National Research Institute - Wilshire
    Los Angeles, California 90057, United States
  • Clinical Pharmacology of Miami, LLC
    Hialeah, Florida 33014, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Mar 2019, 11 months.

Results were first posted in Jun 2021, 2 years 3 months after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2018
First posted
Jan 23, 2018
StartActual
Apr 2, 2018
Primary completionActual
Mar 8, 2019
CompletionActual
Jun 27, 2019
Results first posted
Jun 15, 2021
Last update
Jun 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03406377
Lead sponsor
OPKO Health, Inc.
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Apr 2, 2018
Primary completion
Mar 8, 2019
Completion
Jun 27, 2019
Results posted
Jun 15, 2021
Last update
Jun 15, 2021

Study contacts

Militza Vera De Alba, MD
study director · OPKO Health, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion